Nyrada (ASX:NYR) completed preclinical studies for its stroke therapy NYR-BI03 ahead of a proposed phase one trial, according to a Wednesday filing with the Australian bourse.
The studies showed that the therapy was safe and well tolerated, with results from a rat toxicology report to be used to support the trial submission to the human ethics research committee, the filing said.
The drug development firm anticipates the phase one trial to start later in the year, as per the filing.
The company climbed past 31% in recent Wednesday trade.
Price (AUD): $0.13, Change: $+0.03, Percent Change: +31.31%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。